48.4 vasopressin receptor antagonism as a potential treatment option for the core symptoms of asd: results of balovaptan from early development

The goal of this session is to describe the rationale for vasopressin 1a receptor (V1a) antagonism as a mechanism of action for the potential pharmacotherapy of core social and communication deficits in ASD. In addition, findings on the efficacy and safety of balovaptan, a selective V1a antagonist in early clinical development, will be reviewed.
Source: Journal of the American Academy of Child and Adolescent Psychiatry - Category: Psychiatry Authors: Source Type: research